Table 3. Univariate and multivariate analyses of overall survival in various gastric cancer patient subgroups, according to CPCC.

			Univariate		Multivariatea
Subgroup	Group	N	HR (95% CI)	P	HR (95% CI)	P
Male	Group 1 (⩽6)	107	1		1
	Group 2 (7–17)	103	0.95 (0.60–1.51)	0.835	0.71 (0.42–1.21)	0.206
	Group 3 (⩾18)	91	1.45 (0.93–2.25)	0.097	1.09 (0.66–1.83)	0.715
T1 or T2 male	Group 1 (⩽6)	62	1		1
	Group 2 (7–17)	50	0.55 (0.17–1.77)	0.315	1.42 (0.38–5.33)	0.602
	Group 3 (⩾18)	46	2.36 (1.02–5.46)	0.045	3.05 (1.06–8.76)	0.039
T3 or T4 male	Group 1 (⩽6)	45	1		1
	Group 2 (7–17)	53	0.83 (0.50–1.37)	0.461	0.75 (0.40–1.43)	0.386
	Group 3 (⩾18)	45	1.05 (0.62–1.77)	0.854	0.88 (0.46–1.66)	0.684
Female	Group 1 (⩽4)	50	1		1
	Group 2 (5–13)	42	1.03 (0.50–2.14)	0.935	1.68 (0.59–4.81)	0.333
	Group 3 (⩾14)	44	0.75 (0.35–1.62)	0.467	0.88 (0.36–2.14)	0.773

Abbreviations: CI, confidence interval; CPCC, chromatin CKAP2 (cytoskeleton-associated protein 2)-positive cell count; HR, hazard regression.

^aMultivariate analysis with a Cox proportional hazard regression model was used with the co-variables of age, T stage, N stage, histology, tumor location, tumor size, and adjuvant chemotherapy. All patients included in the univariate analysis were also included in the multivariate analysis.

Significant values are shown in bold.